Chinese oncology player is the latest to join the North Carolina manufacturing party with 2 new plants in the offing

SourceEndpoints News
Date Published05/24/2021
Author NameJosh Sullivan
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name CARsgen Therapeutics
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Total number of jobs (added or to be added):200
Year reshoring announced:2021
Domestically, the work will be done:In-house
Capital investment ($):157
Country(ies) from which reshored:China
City reshored to:Raleigh-Durham
State(s) reshored to:NC
If relevant, work nearshored to:-
Product(s) reshoredCAR-T cell therapies
Find Reshoring Articles